A certified, prerecorded webinar for Nuclear Medicine Technologists who image patients presenting with known or suspected neuroendocrine tumors.
Format: Archived Webinar
MD Credit: no AMA-PRA credit available
RT Credit: 0.75 CEHs ARRT Category A continuing education credit
Fee for Credit Certificate: $0
Click the ENROLL NOW button (left) to register for this program
Course Overview
In the past few decades, the overall incidence of neuroendocrine tumors (NETs) has increased, partly because of improved detection rates.1 Nevertheless, patients typically experience long delays usually of 5-7 years before diagnosis of NETs, as these tumors display an array of symptoms and there is a lack of sensitive and specific methods for early detection.2 Approximately 20% of patients with NETs have metastatic disease at presentation, and in half of those patients the primary tumor is not located at initial imaging.1
Somatostatin receptor scintigraphy (SRS) may be informative in imaging patients with newly diagnosed or suspected neuroendocrine tumors. This educational activity discusses the role of the somatostatin hormone and its impact on the body, the relationship between somatostatin receptors (SSTR) and neuroendocrine tumors (NETS), types of NETS, the role of somatostatin receptor scintigraphy (SRS) in the imaging of NETS, case study review, and challenges and pitfalls of SRS.
Educational Objectives
At the conclusion of this activity, participants should be better able to:
Accreditation and Credit
The SNMMITS, through its Verification Of Involvement in Continuing Education (VOICE) program, has approved this educational activity for a maximum of 0.75 continuing education hours (CEHs) ARRT Category A continuing education credit.
HOW TO PARTICIPATE
There are no fees to participate in this activity.
Please note: The WebEx platform will play on desktop or laptop computers only. It will not play on mobile devices.
HOW TO RECEIVE CREDIT
FACULTY BIOGRAPHY
Dr. Campeau earned his medical degree from Louisiana State Medical Center in New Orleans and completed his residency in Internal Medicine at Tulane University Medical Center in New Orleans. He completed a fellowship in radiology (nuclear medicine) at the Johns Hopkins Hospital in Baltimore. Dr. Campeau is board certified in the specialties of internal medicine and nuclear medicine. He is past present of the American College of Nuclear Medicine and the Southwestern Chapter of the Society of Nuclear Medicine.
Dr. Campeau has been in academic radiology and internal medicine for virtually all of his professional life and believes strongly in the residency program concept first introduced in the United States by Sir William Osler, with attainment of medical knowledge through practice-based learning and improvement, professionalism, and emphasis on interpersonal and communication skills in providing the best patient care possible.
Dr. Campeau is a Fellow of the American College of Nuclear Medicine (FACNM) and a Diplomat of the Certification Board of Nuclear Cardiology (CBNC). He is a founding member of the Society of Cardiovascular Computed Tomography (SCCT). He has a strong interest in the fields of nuclear cardiology, oncology, and endocrinology.
Dr. Campeau has authored more than 40 publications including book chapters and has provided more than 150 presentations and scientific exhibits.
QUESTIONS
For questions regarding this program, please contact ICPME:
Email: information@icpmed.com
Phone: 607-257-5860 X10
Jointly Sponsored by International Center for Postgraduate Medical Education
and North American Neuroendocrine Tumor Society
Funding provided by
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.